Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: Feasibility

Radiology

Volumn 245, Issue 2, 2007, Pages 507-516

  Scheenen, Tom W J ^a   Heijmink, Stijn W T P J ^a   Roell, Stefan A ^b   Hulsbergen Van De Kaa, Christina A ^a   Knipscheer, Ben C ^a   Witjes, J Alfred ^a   Barentsz, Jelle O ^a   Heerschap, Arend ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SIEMENS AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CITRIC ACID; CREATINE;

ADULT; AGED; APPARATUS; ARTICLE; AUTOMATION; CALCULATION; CHOLINE PLUS CREATINE TO CITRATE RATIO; CLINICAL ARTICLE; DEVICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EXTERNAL RADIOFREQUENCY SURFACE COIL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE PROCESSING; IMAGING SYSTEM; INFORMED CONSENT; MALE; MATHEMATICAL ANALYSIS; MEASUREMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOFREQUENCY; SENSITIVITY AND SPECIFICITY; SIGNAL DETECTION; STANDARD; THREE DIMENSIONAL IMAGING;

AGED; FEASIBILITY STUDIES; HUMANS; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RECTUM; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 35348988703     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2451061444     Document Type: Article

References (24)

1. 3) spatial resolution. Radiology 1996;198:795-805.
2. Heerschap A, Jager GJ, van der Graaf M, et al. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res 1997;17:1455-1460.
3. Kurhanewicz J, Vigneron DB, Nelson SJ, et al. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology 1995;45:459-466.
4. Lichy MP, Pintaske J, Kottke R, et al. 3D proton MR spectroscopic imaging of prostate cancer using a standard spine coil at 1.5 T in clinical routine: a feasibility study. Eur Radiol 2005;15:653-600.
5. Brown MA. Time-domain combination of MR spectroscopy data acquired using phased-array coils. Magn Reson Med 2004;52:1207-1213.
6. Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 1987;508:333-348.
7. Scheenen TW, Gambarota G, Weiland E, et al. Optimal timing for in vivo (1)H-MR spectroscopic imaging of the human prostate at 3T. Magn Reson Med 2005;53:1268-1274.
8. van der Graaf M, Schipper RG, Oosterhof GO, Schalken JA, Verhofstad AA, Heerschap A. Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. Magma 2000;10:153-159.
9. Hennig J, Scheffler K. Hyperechoes. Magn Reson Med 2001;46:6-12.
10. Wilman AH, Allen PS. The response of the strongly coupled AB system of citrate to typical 1H MRS localization sequences. J Magn Reson B 1995;107:25-33.
11. Mescher M, Tannus A, Johnson MO, Garwood M. Solvent suppression using selective echo dephasing. J Magn Reson A 1996;123:226-229.
12. Star-Lack J, Nelson SJ, Kurhanewicz J, Huang LR, Vigneron DB. Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING). Magn Reson Med 1997;38:311-321.
13. Scheenen TW, Klomp DW, Roll SA, Futterer JJ, Barentsz JO, Heerschap A. Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate. Magn Reson Med 2004;52:80-88.
14. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York, NY: Springer-Verlag, 2002.
15. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005;234:804-814.
16. Jager GJ, Ruijter ET, van de Kaa CA, et al. Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR Am J Roentgenol 1996;166:845-852.
17. Males RG, Vigneron DB, Star-Lack O, et al. Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging. Magn Reson Med 2000;43:17-22.
18. van Dorsten FA, van der Graaf M, Engelbrecht MR, et al. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 2004;20:279-287.
19. Augustin H, Hammerer PG, Graefen M, et al. Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. Eur Urol 2003;43:455-460.
20. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71:933-938.
21. Futterer JJ, Scheenen TW, Huisman HJ, et al. Initial experience of 3 Tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Invest Radiol 2004;39:671-680.
22. Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006;241:449-458.
23. Jung JA, Coakley FV, Vigneron DB, et al. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004;233:701-708.
24. Scheenen T, van Hecke P, Bachert P, et al. First results of IMAPS: an international multi-centre assessment of prostate MR spectroscopy [abstr]. In: Radiological Society of North America scientific assembly and annual meeting program. Oak Brook, Ill: Radiological Society of North America, 2005; 419.